Therapeutics: Exportin 1 (XPO1; CRM1)

In vitro and mouse studies suggest CRM1 inhibitors could help treat MS. CRM1 levels were higher in cortical MS lesions and other brain tissue of MS patients than in cortical brain tissue from healthy controls. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, an oral CRM1 inhibitor administrated before the onset of symptoms or after the onset of paralysis decreased disease progression, axon damage and immune cell infiltration into the spinal cord compared with vehicle. In a mouse model of kainic acid-induced hippocampal axon damage, the CRM1 inhibitor decreased damage compared with vehicle. Next steps include selecting a CRM1 inhibitor as a clinical candidate...